Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30777653 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL554095 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL25423836 | 0.97 | BCL2L1 (0.94) | BCL2L1BCL2 | |
| SCHEMBL25423839 | 0.97 | BCL2L1 (0.94) | BCL2L1BCL2 | |
| SCHEMBL22879158 | 0.93 | BCL2L1 (0.87) | BCL2L1BCL2 | |
| SCHEMBL24633503 | 0.93 | BCL2L1 (0.87) | BCL2L1BCL2 | |
| SCHEMBL29424547 | 0.93 | BCL2L1 (0.87) | BCL2L1BCL2 | |
| SCHEMBL31570836 | 0.92 | BCL2L1 (0.85) | BCL2L1BCL2 | |
| SCHEMBL30405101 | 0.92 | BCL2L1 (0.85) | BCL2L1BCL2 | |
| SCHEMBL19145119 | 0.91 | BCL2L1 (0.84) | BCL2L1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118139835-A | Method for preparing apoptosis inducer | 艾伯维公司 | 2024-06-04 | — | — | CN | claimed |
| EP-2307393-B1 | A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 | ABBOTT LAB (US) | 2013-04-10 | — | — | EP | claimed |
| US-8168784-B2 | Processes to make apoptosis promoters | ABBOTT LABORATORIES (US) | 2012-05-01 | — | — | US | claimed |
| JP-2011525182-A | — | — | 2011-09-15 | — | — | JP | claimed |
| EP-2307393-A1 | A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | claimed |
| US-20090318689-A1 | Processes To Make Apoptosis Promoters | ABBOTT LABORATORIES (US) | 2009-12-24 | — | — | US | claimed |
| WO-2009155386-A1 | A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 | ABBOTT LABORATORIES (US) | 2009-12-23 | — | — | WO | claimed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-RE50643-E1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4556469-A1 | BENZAMIDE COMPOUNDS | Recurium IP Holdings, LLC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3740487-B1 | BENZAMIDE COMPOUNDS AS BCI INHIBITORS FOR THE TREATMENT OF HIV | RECURIUM IP HOLDINGS LLC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240180899-A1 | BENZAMIDE COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2024-06-06 | — | — | US | disclosed |
| CN-118139835-A | Method for preparing apoptosis inducer | 艾伯维公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20090318689-A1 | Processes To Make Apoptosis Promoters | ABBOTT LABORATORIES (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009155386-A1 | A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 | ABBOTT LABORATORIES (US) | 2009-12-23 | — | — | WO | disclosed |
| EP-1953161-B1 | New tricyclic derivatives, method of preparing same and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008110691-A1 | NOVEL TRICYCLIC DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2008-09-18 | — | — | WO | disclosed |
| US-20080188460-A1 | Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2008-08-07 | — | — | US | disclosed |
| EP-1953161-A1 | New tricyclic derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2008-08-06 | — | — | EP | disclosed |
| WO-2008064116-A2 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318689-A1 | Processes To Make Apoptosis Promoters | BAX, BCL2, CCAR2 | BCL2L1 28/4885BCL2 2/4885 |
| US-20240180899-A1 | BENZAMIDE COMPOUNDS | MKI67, TMBIM6, HDAC1 | BCL2L1 86/4885BCL2 69/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | BCL2L1 3/4885BCL2 4/4885 |
| US-20080188460-A1 | Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them | BAX, BCL2, CASP3 | BCL2L1 45/4885BCL2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.